- Home
- HGTY vs EVO Comparison
HGTY vs EVO Comparison
Compare HGTY & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- EVO
- Stock Information
- Founded
- HGTY 1984
- EVO 1993
- Country
- HGTY United States
- EVO Germany
- Employees
- HGTY N/A
- EVO N/A
- Industry
- HGTY Specialty Insurers
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- HGTY Finance
- EVO Health Care
- Exchange
- HGTY Nasdaq
- EVO Nasdaq
- Market Cap
- HGTY 1.1B
- EVO 1.2B
- IPO Year
- HGTY N/A
- EVO 2021
- Fundamental
- Price
- HGTY $12.01
- EVO $4.01
- Analyst Decision
- HGTY Hold
- EVO Buy
- Analyst Count
- HGTY 7
- EVO 2
- Target Price
- HGTY $13.33
- EVO $5.40
- AVG Volume (30 Days)
- HGTY 219.4K
- EVO 44.2K
- Earning Date
- HGTY 11-06-2025
- EVO 11-05-2025
- Dividend Yield
- HGTY N/A
- EVO N/A
- EPS Growth
- HGTY 90.09
- EVO N/A
- EPS
- HGTY 0.20
- EVO N/A
- Revenue
- HGTY $1,303,397,000.00
- EVO $912,894,891.00
- Revenue This Year
- HGTY $15.91
- EVO $0.39
- Revenue Next Year
- HGTY $1.94
- EVO $9.53
- P/E Ratio
- HGTY $59.00
- EVO N/A
- Revenue Growth
- HGTY 17.90
- EVO N/A
- 52 Week Low
- HGTY $8.03
- EVO $2.84
- 52 Week High
- HGTY $13.32
- EVO $5.64
- Technical
- Relative Strength Index (RSI)
- HGTY 51.06
- EVO 66.01
- Support Level
- HGTY $11.75
- EVO $3.47
- Resistance Level
- HGTY $12.46
- EVO $3.70
- Average True Range (ATR)
- HGTY 0.40
- EVO 0.09
- MACD
- HGTY -0.11
- EVO 0.05
- Stochastic Oscillator
- HGTY 22.49
- EVO 100.00
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.